Gain Therapeutics (NASDAQ:GANX) Rating Reiterated by HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $9.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 197.03% from the stock’s previous close.

A number of other equities research analysts have also commented on GANX. Chardan Capital reiterated a “buy” rating and set a $6.00 price target on shares of Gain Therapeutics in a report on Wednesday, March 27th. Oppenheimer reiterated an “outperform” rating and set a $9.00 price target on shares of Gain Therapeutics in a report on Tuesday.

Gain Therapeutics Trading Down 1.3 %

GANX stock opened at $3.03 on Thursday. The company has a market capitalization of $49.15 million, a PE ratio of -1.77 and a beta of 0.43. Gain Therapeutics has a one year low of $2.00 and a one year high of $5.65. The company’s 50 day moving average price is $3.97 and its two-hundred day moving average price is $3.44. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.59 and a current ratio of 3.59.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Tuesday, March 26th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03. As a group, analysts predict that Gain Therapeutics will post -1.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Gain Therapeutics

In related news, Director Jeffrey Scott Riley acquired 30,000 shares of Gain Therapeutics stock in a transaction on Thursday, March 28th. The shares were acquired at an average cost of $3.86 per share, with a total value of $115,800.00. Following the transaction, the director now owns 30,000 shares in the company, valued at $115,800. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 11.00% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.